These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33187969)

  • 1. Shorter Treatment-Naïve Leukocyte Telomere Length is Associated with Poorer Overall Survival of Patients with Pancreatic Ductal Adenocarcinoma.
    Antwi SO; Bamlet WR; Cawthon RM; Rabe KG; Druliner BR; Sicotte H; Jatoi A; Mahipal A; Boardman LA; Oberg AL; Petersen GM
    Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):210-216. PubMed ID: 33187969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukocyte Telomere Length and Its Interaction with Germline Variation in Telomere-Related Genes in Relation to Pancreatic Adenocarcinoma Risk.
    Antwi SO; Bamlet WR; Rabe KG; Cawthon RM; Umudi I; Druliner BR; Sicotte H; Oberg AL; Jatoi A; Boardman LA; Petersen GM
    Cancer Epidemiol Biomarkers Prev; 2020 Jul; 29(7):1492-1500. PubMed ID: 32312758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study.
    Campa D; Matarazzi M; Greenhalf W; Bijlsma M; Saum KU; Pasquali C; van Laarhoven H; Szentesi A; Federici F; Vodicka P; Funel N; Pezzilli R; Bueno-de-Mesquita HB; Vodickova L; Basso D; Obazee O; Hackert T; Soucek P; Cuk K; Kaiser J; Sperti C; Lovecek M; Capurso G; Mohelnikova-Duchonova B; Khaw KT; König AK; Kupcinskas J; Kaaks R; Bambi F; Archibugi L; Mambrini A; Cavestro GM; Landi S; Hegyi P; Izbicki JR; Gioffreda D; Zambon CF; Tavano F; Talar-Wojnarowska R; Jamroziak K; Key TJ; Fave GD; Strobel O; Jonaitis L; Andriulli A; Lawlor RT; Pirozzi F; Katzke V; Valsuani C; Vashist YK; Brenner H; Canzian F
    Int J Cancer; 2019 Mar; 144(6):1275-1283. PubMed ID: 30325019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
    Yin JB; Li N; Cui MM; Wang X; Wang RT
    BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma.
    Gao Y; Wang M; Guo X; Hu J; Chen TM; Finn SMB; Lacy J; Kunstman JW; Cha CH; Bellin MD; Robert ME; Desir GV; Gorelick FS
    PLoS One; 2021; 16(9):e0250539. PubMed ID: 34587190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
    Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
    Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-treatment serum vitamin D deficiency is associated with increased inflammatory biomarkers and short overall survival in patients with pancreatic cancer.
    Rasmussen LS; Yilmaz MK; Falkmer UG; Poulsen LØ; Bøgsted M; Christensen HS; Bojesen SE; Jensen BV; Chen IM; Johansen AZ; Hansen CP; Hasselby JP; Holländer N; Nielsen SE; Andersen F; Bjerregaard JK; Pfeiffer P; Johansen JS
    Eur J Cancer; 2021 Feb; 144():72-80. PubMed ID: 33341448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
    Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.
    Xiao Y; Chen W; Xie Z; Shao Z; Xie H; Qin G; Zhao N
    BMC Cancer; 2017 Jan; 17(1):25. PubMed ID: 28056913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leukocyte telomere length in relation to pancreatic cancer risk: a prospective study.
    Campa D; Mergarten B; De Vivo I; Boutron-Ruault MC; Racine A; Severi G; Nieters A; Katzke VA; Trichopoulou A; Yiannakouris N; Trichopoulos D; Boeing H; Quirós JR; Duell EJ; Molina-Montes E; Huerta JM; Ardanaz E; Dorronsoro M; Khaw KT; Wareham N; Travis RC; Palli D; Pala V; Tumino R; Naccarati A; Panico S; Vineis P; Riboli E; Siddiq A; Bueno-de-Mesquita HB; Peeters PH; Nilsson PM; Sund M; Ye W; Lund E; Jareid M; Weiderpass E; Duarte-Salles T; Kong SY; Stepien M; Canzian F; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2447-54. PubMed ID: 25103821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
    Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
    Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
    Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
    World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic fibrosis, acinar atrophy and chronic inflammation in surgical specimens associated with survival in patients with resectable pancreatic ductal adenocarcinoma.
    Korpela T; Ristimäki A; Udd M; Vuorela T; Mustonen H; Haglund C; Kylänpää L; Seppänen H
    BMC Cancer; 2022 Jan; 22(1):23. PubMed ID: 34980011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukocyte Telomere Length and Risks of Incident Coronary Heart Disease and Mortality in a Racially Diverse Population of Postmenopausal Women.
    Carty CL; Kooperberg C; Liu J; Herndon M; Assimes T; Hou L; Kroenke CH; LaCroix AZ; Kimura M; Aviv A; Reiner AP
    Arterioscler Thromb Vasc Biol; 2015 Oct; 35(10):2225-31. PubMed ID: 26249011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis.
    Zhang K; Dong S; Jing YH; Gao HF; Chen LY; Hua YQ; Chen H; Chen Z
    BMC Cancer; 2020 Jun; 20(1):541. PubMed ID: 32517802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum gamma-glutamyltransferase and the overall survival of metastatic pancreatic cancer.
    Xiao Y; Yang H; Lu J; Li D; Xu C; Risch HA
    BMC Cancer; 2019 Oct; 19(1):1020. PubMed ID: 31664937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nomogram based on preoperative inflammatory markers predicting the overall survival of pancreatic ductal adenocarcinoma.
    Xu J; Shi KQ; Chen BC; Huang ZP; Lu FY; Zhou MT
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1394-1402. PubMed ID: 27973703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.